T Cell Therapy Targeted on HLA-A02 Restricted HIV Antigen Epitopes: An Open Label Cellular Therapy Trial Using CD8+ T Cell
Objective: To test the safety and efficacy of a T cell therapy de novo targeting HLA-A02 restricted HIV antigen epitopes.Design: This was a prospective open label clinical trial, which enrolled 28 HIV+ participants and 24 of them finished the trial. The study was publicly registered at Chinese Clini...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-03-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.00437/full |
id |
doaj-3f82e9a2adea4e1f8502d8966408f43b |
---|---|
record_format |
Article |
spelling |
doaj-3f82e9a2adea4e1f8502d8966408f43b2020-11-25T02:16:32ZengFrontiers Media S.A.Frontiers in Immunology1664-32242019-03-011010.3389/fimmu.2019.00437397377T Cell Therapy Targeted on HLA-A02 Restricted HIV Antigen Epitopes: An Open Label Cellular Therapy Trial Using CD8+ T CellSai Liu0Jianping Sun1Zhen Li2Ling Qin3Guihai Liu4Kang Li5Hao Wu6Tao Dong7Yonghong Zhang8Biomarkers of Infection Related Diseases Beijing Key Laboratory, Beijing You'An Hospital, Capital Medical University, Beijing, ChinaBiomarkers of Infection Related Diseases Beijing Key Laboratory, Beijing You'An Hospital, Capital Medical University, Beijing, ChinaCenter of Infectious Disease, Beijing You'An Hospital, Capital Medical University, Beijing, ChinaBiomarkers of Infection Related Diseases Beijing Key Laboratory, Beijing You'An Hospital, Capital Medical University, Beijing, ChinaBiomarkers of Infection Related Diseases Beijing Key Laboratory, Beijing You'An Hospital, Capital Medical University, Beijing, ChinaBiomarkers of Infection Related Diseases Beijing Key Laboratory, Beijing You'An Hospital, Capital Medical University, Beijing, ChinaCenter of Infectious Disease, Beijing You'An Hospital, Capital Medical University, Beijing, ChinaMedical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford University, Oxford, United KingdomBiomarkers of Infection Related Diseases Beijing Key Laboratory, Beijing You'An Hospital, Capital Medical University, Beijing, ChinaObjective: To test the safety and efficacy of a T cell therapy de novo targeting HLA-A02 restricted HIV antigen epitopes.Design: This was a prospective open label clinical trial, which enrolled 28 HIV+ participants and 24 of them finished the trial. The study was publicly registered at Chinese Clinical Trial Registry, www.chictr.org.cn(ChiCTR-ICR-15005775).Method: Autologous peripheral blood mononuclear cells were co-cultured with HLA-A02 restricted HIV antigen epitopes peptides to produce cell product for this therapy. The trial was divided into five time-points with the same interval period for infusion of the cell products or monitoring parameters. Symptoms, vital signs, and blood samples were collected to analyze the safety and efficacy of this therapy.Results: Two cases of adverse effects happened during this trial in test group, which recovered without medical intervention. There was no severe adverse effect that occurred. Both symptoms and laboratory tests have no statistical significant difference between test and control group. Flowcytometry analysis showed the expression of the PD-1 and CD95 molecule on the cell surface were downregulated post-treatment in the test group.Conclusions: This autologous HIV-antigen specific effector CD8+ T cellular therapy was safe. It might have an impact on immune suppression that can provide useful reference to future cell therapy trials.https://www.frontiersin.org/article/10.3389/fimmu.2019.00437/fullT cellscellular immunityantigen epitopescellular therapiesHIVHLA-A02 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sai Liu Jianping Sun Zhen Li Ling Qin Guihai Liu Kang Li Hao Wu Tao Dong Yonghong Zhang |
spellingShingle |
Sai Liu Jianping Sun Zhen Li Ling Qin Guihai Liu Kang Li Hao Wu Tao Dong Yonghong Zhang T Cell Therapy Targeted on HLA-A02 Restricted HIV Antigen Epitopes: An Open Label Cellular Therapy Trial Using CD8+ T Cell Frontiers in Immunology T cells cellular immunity antigen epitopes cellular therapies HIV HLA-A02 |
author_facet |
Sai Liu Jianping Sun Zhen Li Ling Qin Guihai Liu Kang Li Hao Wu Tao Dong Yonghong Zhang |
author_sort |
Sai Liu |
title |
T Cell Therapy Targeted on HLA-A02 Restricted HIV Antigen Epitopes: An Open Label Cellular Therapy Trial Using CD8+ T Cell |
title_short |
T Cell Therapy Targeted on HLA-A02 Restricted HIV Antigen Epitopes: An Open Label Cellular Therapy Trial Using CD8+ T Cell |
title_full |
T Cell Therapy Targeted on HLA-A02 Restricted HIV Antigen Epitopes: An Open Label Cellular Therapy Trial Using CD8+ T Cell |
title_fullStr |
T Cell Therapy Targeted on HLA-A02 Restricted HIV Antigen Epitopes: An Open Label Cellular Therapy Trial Using CD8+ T Cell |
title_full_unstemmed |
T Cell Therapy Targeted on HLA-A02 Restricted HIV Antigen Epitopes: An Open Label Cellular Therapy Trial Using CD8+ T Cell |
title_sort |
t cell therapy targeted on hla-a02 restricted hiv antigen epitopes: an open label cellular therapy trial using cd8+ t cell |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2019-03-01 |
description |
Objective: To test the safety and efficacy of a T cell therapy de novo targeting HLA-A02 restricted HIV antigen epitopes.Design: This was a prospective open label clinical trial, which enrolled 28 HIV+ participants and 24 of them finished the trial. The study was publicly registered at Chinese Clinical Trial Registry, www.chictr.org.cn(ChiCTR-ICR-15005775).Method: Autologous peripheral blood mononuclear cells were co-cultured with HLA-A02 restricted HIV antigen epitopes peptides to produce cell product for this therapy. The trial was divided into five time-points with the same interval period for infusion of the cell products or monitoring parameters. Symptoms, vital signs, and blood samples were collected to analyze the safety and efficacy of this therapy.Results: Two cases of adverse effects happened during this trial in test group, which recovered without medical intervention. There was no severe adverse effect that occurred. Both symptoms and laboratory tests have no statistical significant difference between test and control group. Flowcytometry analysis showed the expression of the PD-1 and CD95 molecule on the cell surface were downregulated post-treatment in the test group.Conclusions: This autologous HIV-antigen specific effector CD8+ T cellular therapy was safe. It might have an impact on immune suppression that can provide useful reference to future cell therapy trials. |
topic |
T cells cellular immunity antigen epitopes cellular therapies HIV HLA-A02 |
url |
https://www.frontiersin.org/article/10.3389/fimmu.2019.00437/full |
work_keys_str_mv |
AT sailiu tcelltherapytargetedonhlaa02restrictedhivantigenepitopesanopenlabelcellulartherapytrialusingcd8tcell AT jianpingsun tcelltherapytargetedonhlaa02restrictedhivantigenepitopesanopenlabelcellulartherapytrialusingcd8tcell AT zhenli tcelltherapytargetedonhlaa02restrictedhivantigenepitopesanopenlabelcellulartherapytrialusingcd8tcell AT lingqin tcelltherapytargetedonhlaa02restrictedhivantigenepitopesanopenlabelcellulartherapytrialusingcd8tcell AT guihailiu tcelltherapytargetedonhlaa02restrictedhivantigenepitopesanopenlabelcellulartherapytrialusingcd8tcell AT kangli tcelltherapytargetedonhlaa02restrictedhivantigenepitopesanopenlabelcellulartherapytrialusingcd8tcell AT haowu tcelltherapytargetedonhlaa02restrictedhivantigenepitopesanopenlabelcellulartherapytrialusingcd8tcell AT taodong tcelltherapytargetedonhlaa02restrictedhivantigenepitopesanopenlabelcellulartherapytrialusingcd8tcell AT yonghongzhang tcelltherapytargetedonhlaa02restrictedhivantigenepitopesanopenlabelcellulartherapytrialusingcd8tcell |
_version_ |
1724890614791667712 |